{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:25:29Z","timestamp":1776090329904,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1016\/j.pcad.2004.04.005","type":"journal-article","created":{"date-parts":[[2004,12,16]],"date-time":"2004-12-16T13:06:54Z","timestamp":1103202414000},"page":"105-115","source":"Crossref","is-referenced-by-count":23,"title":["Angiotensin II receptor antagonists: Role in hypertension, cardiovascular disease, and renoprotection"],"prefix":"10.1016","volume":"47","author":[{"given":"Gerald B.","family":"Appel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice S.","family":"Appel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2004.04.005_BIB1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev.pa.36.040196.001433","article-title":"Angiotensin receptors and their therapeutic implications","volume":"36","author":"Griendling","year":"1996","journal-title":"Ann Rev Pharmacol Toxicol"},{"key":"10.1016\/j.pcad.2004.04.005_BIB2","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/00004872-199917070-00002","article-title":"Non-peptide angiotensin type I receptor antagonists in the treatment of hypertension","volume":"17","author":"Birkenhager","year":"1999","journal-title":"J Hypertens"},{"issue":"Suppl","key":"10.1016\/j.pcad.2004.04.005_BIB3","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1046\/j.1523-1755.1998.06822.x","article-title":"Angiotensin II receptor antagonists in hypertension","volume":"68","author":"Burnier","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.pcad.2004.04.005_BIB4","first-page":"205","article-title":"Angiotensin II receptors and angiotensin II receptor antagonists","volume":"45","author":"Timmermans","year":"1993","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pcad.2004.04.005_BIB5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(99)10365-9","article-title":"Angiotensin II receptor antagonists","volume":"355","author":"Burnier","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2004.04.005_BIB6","first-page":"607","article-title":"Identification of metabolic pathways of brain angiotensin II and angiotensin III","volume":"192","author":"Llorens-Cortes","year":"1998","journal-title":"C R Seances Soc Biol Fil"},{"key":"10.1016\/j.pcad.2004.04.005_BIB7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0165-0173(97)00019-2","article-title":"Important role for angiotensin III and IV in the brain renin-angiotensin system","volume":"25","author":"Wright","year":"1997","journal-title":"Brain Res Rev"},{"key":"10.1016\/j.pcad.2004.04.005_BIB8","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1021\/bi972863j","article-title":"Characterization of AT4 receptor from bovine aortic endothelium with photosensitive analogues of angiotensin IV","volume":"37","author":"Bernier","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.pcad.2004.04.005_BIB9","first-page":"F290","article-title":"Angiotensin IV AT4-receptor system in the rat kidney","volume":"274","author":"Handa","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pcad.2004.04.005_BIB10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00004872-199917030-00013","article-title":"Angiotensin II type 1 and type 2 receptors bind angiotensin II through different types of epitope recognition","volume":"17","author":"Miura","year":"1999","journal-title":"J Hypertens"},{"key":"10.1016\/j.pcad.2004.04.005_BIB11","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/01.HYP.33.2.613","article-title":"Recent progress in angiotensin II type 2 receptor research in the cardiovascular system","volume":"33","author":"Horiuchi","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2004.04.005_BIB12","first-page":"557","article-title":"Cross-talk between angiotensin II receptors and the tyrosine kinases and phosphatases","volume":"10","author":"Inagami","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pcad.2004.04.005_BIB13","first-page":"753","article-title":"Functional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism","volume":"273","author":"Panek","year":"1995","journal-title":"J Pharm Exp Ther"},{"key":"10.1016\/j.pcad.2004.04.005_BIB14","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/sj.bjp.0702398","article-title":"Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors","volume":"126","author":"Vanderheyden","year":"1999","journal-title":"Br J Pharmachol"},{"key":"10.1016\/j.pcad.2004.04.005_BIB15","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/ajh\/7.12.1041","article-title":"Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension","volume":"7","author":"Grossman","year":"1994","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pcad.2004.04.005_BIB16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1161\/01.HYP.26.1.112","article-title":"Effects of losartan on a background of hydrochlorothiazide in patients with hypertension","volume":"26","author":"Soffer","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2004.04.005_BIB17","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1097\/00004872-199511000-00017","article-title":"Comparison of the angiotensin II antagonist losartan with the ACE inhibitor enalapril in patients with essential hypertension","volume":"13","author":"Tikkanen","year":"1995","journal-title":"J Hypertens"},{"key":"10.1016\/j.pcad.2004.04.005_BIB18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0002-9149(99)80413-5","article-title":"Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension","volume":"75","author":"Goldberg","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2004.04.005_BIB19","first-page":"549","article-title":"Association between cough and angiotensin converting enzyme inhibitory versus angiotensin II antagonists","volume":"12","author":"Lacourci\u00e8re","year":"1994","journal-title":"J Hypertens"},{"key":"10.1016\/j.pcad.2004.04.005_BIB20","first-page":"1387","article-title":"Effects of modulators of the renin-angiotensin-aldosterone system on cough","volume":"12","author":"Lacourci\u00e8re","year":"1994","journal-title":"J Hypertens"},{"key":"10.1016\/j.pcad.2004.04.005_BIB21","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/01.CIR.104.3.281","article-title":"Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma","volume":"104","author":"Tanaka","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2004.04.005_BIB22","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1001\/archinte.158.18.2063","article-title":"Angioneurotic edema attributed to the use of losartan","volume":"158","author":"van Rijnsoever","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pcad.2004.04.005_BIB23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0140-6736(00)03648-5","article-title":"Losartan and fetal toxic effects","volume":"357","author":"Saji","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2004.04.005_BIB24","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/j.1523-1755.2000.00381.x","article-title":"ACE inhibition or angiotensin receptor blockade","volume":"58","author":"Bakris","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.pcad.2004.04.005_BIB25","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","article-title":"Molecular identification of renal urate anion exchanger that regulates blood urate levels","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.pcad.2004.04.005_BIB26","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC VII Report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2004.04.005_BIB27","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE)","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2004.04.005_BIB28","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","article-title":"Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE)","volume":"359","author":"Lindholm","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2004.04.005_BIB29","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0895-7061(97)00491-3","article-title":"Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension","volume":"11","author":"Kassler-Taub","year":"1998","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pcad.2004.04.005_BIB30","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/sj.jhh.1000925","article-title":"ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension","volume":"13","author":"Mallion","year":"1999","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.pcad.2004.04.005_BIB31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/080370598437574","article-title":"The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan","volume":"7","author":"Andersson","year":"1998","journal-title":"Blood Press"},{"key":"10.1016\/j.pcad.2004.04.005_BIB32","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0895-7061(99)00082-5","article-title":"A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension","volume":"12","author":"Hedner","year":"1999","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pcad.2004.04.005_BIB33","doi-asserted-by":"crossref","first-page":"418426","DOI":"10.1016\/S0895-7061(99)00237-X","article-title":"Angiotensin II antagonists for hypertension","volume":"13","author":"Conlin","year":"2000","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pcad.2004.04.005_BIB34","first-page":"52","article-title":"Comparative effects of candesartan cilexitil and losartan in patients with systemic hypertension","volume":"1","author":"Gradman","year":"1999","journal-title":"Heart Disease"},{"key":"10.1016\/j.pcad.2004.04.005_BIB35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1524-6175.2001.00826.x","article-title":"Antihypertensive efficacy of candesartan in comparison to losartan; The CLAIM Study","volume":"3","author":"Bakris","year":"2001","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.pcad.2004.04.005_BIB36","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/S0140-6736(00)04728-0","article-title":"Progression, remission, and regression of chronic renal disease","volume":"357","author":"Ruggenenti","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2004.04.005_BIB37","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1046\/j.1523-1755.2000.00224.x","article-title":"Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy","volume":"58","author":"LaCouci\u00e8re","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.pcad.2004.04.005_BIB38","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2004.04.005_BIB39","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","article-title":"Microalbuminuric reduction with valsartan in patients with type 2 diabetes","volume":"106","author":"Viberti","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2004.04.005_BIB40","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/ki.1994.113","article-title":"Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?","volume":"45","author":"Gansevort","year":"1994","journal-title":"Kidney Int"},{"key":"10.1016\/j.pcad.2004.04.005_BIB41","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2004.04.005_BIB42","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.2337\/diacare.26.5.1402","article-title":"Analysis of metabolic parameters as predictors of risk in the RENAAL study","volume":"26","author":"Appel","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcad.2004.04.005_BIB43","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2004.04.005_BIB44","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0272-6386(99)70416-6","article-title":"Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy","volume":"33","author":"Russo","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.pcad.2004.04.005_BIB45","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1523-1755.2002.00536.x","article-title":"Dual renin-angiotensin system blockade at optimal doses for proteinuria","volume":"62","author":"Laverman","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.pcad.2004.04.005_BIB46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1523-1755.2003.00832.x","article-title":"Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies","volume":"63","author":"Campbell","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.pcad.2004.04.005_BIB47","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1046\/j.1523-1755.2003.00015.x","article-title":"Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis","volume":"63","author":"Iodice","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.pcad.2004.04.005_BIB48","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","article-title":"Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease (COOPERATE)","volume":"361","author":"Nakao","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2004.04.005_BIB49","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00041552-200405000-00009","article-title":"Single versus dual blockage of the renin-angiotensin system (angiotensin converting enzyme inhibitors and\/or angiotensin II receptor blockers) in diabetic nephropathy","volume":"13","author":"Jacobsen","year":"2004","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.pcad.2004.04.005_BIB50","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","article-title":"Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)","volume":"349","author":"Pitt","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2004.04.005_BIB51","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2004.04.005_BIB52","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2004.04.005_BIB53","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2004.04.005_BIB54","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2004.04.005_BIB55","doi-asserted-by":"crossref","first-page":"9386","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to ACE inhibitors","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2004.04.005_BIB56","doi-asserted-by":"crossref","first-page":"9386","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking ACE inhibitors","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2004.04.005_BIB57","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2004.04.005_BIB58","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062004000210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062004000210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T04:52:33Z","timestamp":1548910353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062004000210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0033062004000210"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2004.04.005","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}